Match made in heaven.

The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

Canadian employers and their employees can expect to see drug plan savings as generic versions of diabetes and obesity medications are introduced, cutting insurance costs. Ozempic and Wegovy – two ...

Mohsen Baqery is a Staff Writer at GameRant based in Turkey. He mainly covers video game news and industry features while occasionally publishing guides and listicles. Mohsen started his journey into ...

Higher-income households are leading the shift to store brands and discount grocers, and most shoppers say private-label quality matches or beats name brands Start with “low-risk” swaps (staples, ...

My little theory is that the concept of “imprinting” in psychology can just as easily be applied to programming: Much as a baby goose decides that the first moving life-form it encounters is its ...

The Food and Drug Administration (FDA) approved a generic version of the abortion pill mifepristone in October, making chemical abortion more affordable and accessible to pregnant women who wish to ...

As of Nov. 3, 140 claims were still pending, according to the Judicial Panel on Multidistrict Litigation. Explore the entire Law.com network. Enjoy free access to one article from the Law.com network ...

PHOENIX — With flu cases rising overseas in countries like the United Kingdom and a new variant identified in Japan, experts warn that the United States could face an earlier flu season this year.

Democrats are up 8 points over Republicans on a generic congressional ballot, according to new polling. In the NBC News survey released Sunday, 50 percent of respondents said they wanted “a Congress ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...